Mack Kenneth

Mack Kenneth, a sole proprietorship based in Rochester, Minnesota, provides medical expert services and specialized case reviews for the Vaccine Injury Compensation Program (VICP) exclusively to the Department of Health and Human Services' Health Resources and Services Administration as a prime contractor under small business set-aside vehicles. Kenneth operates as a one-customer, specialized-service provider with all fifteen awards flowing from HRSA and no subcontract work.

Kenneth's capability footprint is singular and narrow: medical expert opinions and case reviews supporting VICP claim adjudication. All work is performed locally from Rochester. The vendor holds two active indefinite delivery vehicles with HRSA for ongoing medical expert panel services carrying combined potential value of $499,998, and places individual BPA calls against three parent blanket purchase agreements. Recent awards include a firm fixed-price BPA call of $22,500 (HSB114 C 7172, completed February 12, 2027) for VICP medical expert case reviews, a $1,800 BPA call from September 2023, and a $4,500 BPA call from March 2023, all supporting individual VICP case evaluations. Combined potential value across all fifteen awards is $710 thousand, with only $58 thousand obligated (8% of potential), indicating a significant performance backlog or delayed funding on the IDV vehicles.

Customer concentration is absolute: HRSA accounts for 100% of awards and 100% of combined potential value. Activity is sporadic — ranging from one to three awards per year across 2018–2023, then one award in 2026 — with only one award ($23 thousand potential) reaching ultimate completion inside the next twenty-four months. Kenneth competes exclusively under total small business set-aside designations where the source indicates set-aside use, and holds no vehicle seats with other agencies. The vendor's 15-year tenure with HRSA (first award September 2014) and consistent re-award on VICP medical expert calls signals deep specialization in a narrow regulatory niche with limited recompete exposure or growth potential outside HRSA's program scope.